Skip to main content
Respiratory Medicine Thoracic Tumor

Thoracic Tumor

Tracheopericardial fistula masquerading as acute MI

Tracheopericardial fistula is often misdiagnosed due to its rarity and nonspecific presentation. In this patient with recurrent lung cancer, it was initially mistaken for an acute myocardial infarction.

Read more

Editor's Choice

Tobacco and COPD

A review expanding on the recent WHO Tobacco Knowledge Summary on COPD, adding greater detail for pulmonologists. Equip yourself to advocate for the health of your patients and the wider population by understanding and sharing the five key messages.

Pulmonary toxicities of NSCLC systemic therapy

  • Open Access
  • NSCLC
  • Review

Drug-induced pneumonitis is a common side effect of lung cancer systemic therapy. This review provides a detailed management approach for pneumonitis caused by chemotherapy, antibody–drug conjugates, targeted therapy, or immunotherapy.

Concurrent pulmonary cryptococcosis and lung cancer

This case serves as a prompt to consider the possibility of cryptococcosis, even when lung cancer has already been diagnosed, when lung radiology shows multiple nodules.

Chemotherapy resistance in SCLC

Acquired drug resistance is a hallmark of small-cell lung cancer. What are the mechanisms underlying the rapid development of chemotherapy resistance, and how can this knowledge be used to develop novel treatment options?

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Episode 7: A deep dive into ADAURA

The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC. 

We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial.

Dr. Luis Paz-Ares
Listen now

Next-generation sequencing

Next-generation sequencing is a powerful tool that can identify mutations or fusions in a wide range of cancers, enabling physicians to provide targeted therapy to patients and improve outcomes. 

In this vodcast, Professor Andrew Beggs discusses practical aspects of this technique from the clinical viewpoint.

This content is intended only for healthcare providers, excluding UK.

Supported by:
  • Illumina, Inc., and Eli Lilly and Company
Prof. Andrew Beggs
Developed by: Springer Healthcare
Watch now

Case Studies

Tracheopericardial fistula masquerading as acute MI

Tracheopericardial fistula is often misdiagnosed due to its rarity and nonspecific presentation. In this patient with recurrent lung cancer, it was initially mistaken for an acute myocardial infarction.

Concurrent pulmonary cryptococcosis and lung cancer

This case serves as a prompt to consider the possibility of cryptococcosis, even when lung cancer has already been diagnosed, when lung radiology shows multiple nodules.

Adrenal insufficiency caused by immunotherapy

Three patients receiving tislelizumab immunotherapy for NSCLC developed adrenal insufficiency, highlighting the need for awareness of pituitary–adrenal axis dysfunction as an immune-related adverse event.

Current Reviews

Personalized oncology, ethics and adherence to NCCN guidelines

Successful personalized oncology today depends on clinicians taking advantage of the extensive, evidence-based information provided by the National Comprehensive Cancer Network (NCCN) Guidelines, which arguably represent the most important advance …

Vaccine-based therapeutic interventions in lung cancer management: A recent perspective

The incidence of lung cancer continues to grow globally, contributing to an ever-increasing load on healthcare systems. Emerging evidence has indicated lowered efficacy of conventional treatment strategies, such as chemotherapy, surgical …

Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors

The clinical response to immune checkpoint inhibitors may vary by tumor type and many tumors present with either primary or acquired resistance to immunotherapy. Improved understanding of the molecular and immunologic mechanisms underlying …

The effectiveness of exercise interventions on psychological distress in patients with lung cancer: a systematic review and meta-analysis

Lung cancer was identified by the World Health Organization (WHO) as the leading cause of cancer-related mortality, accounting for 1.80 million deaths in 2020 [ 1 ]. In Asia, high incidence and mortality rates of lung cancer have been reported in …

CME & eLearning

Webinar (Link opens in a new window)

1.25 AMA PRA Category 1 Credit(s)

A collaborative program highlighting the importance of molecular assessments and targeted treatment selection in people with biomarker-positive disease. Submit your questions for the experts now.

Supported by:
  • Roche and Illumina
Developed by: Springer Healthcare IME

eLearning | Interviews | Digital Treatment Map (Link opens in a new window)

1.0 AMA PRA Category 1 Credit(s)

Expert-led, multiformat program which will address the individualized management of NSCLC, through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies. Will also include guidance on integrating shared decision making into your clinical practice, drawing on insights from a patient on how best to communicate.

Supported by:
  • Bayer HealthCare Pharmaceuticals Inc.
Developed by: Springer Healthcare IME

Digital Treatment Map (Link opens in a new window)

Practical, expert-led digital map designed to guide treatment of ALK- and ROS1-mutation positive NSCLC.

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME

Further Reading

Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors

The clinical response to immune checkpoint inhibitors may vary by tumor type and many tumors present with either primary or acquired resistance to immunotherapy. Improved understanding of the molecular and immunologic mechanisms underlying …

Triple therapy boosts survival in NSCLC patients with brain metastases: a retrospective cohort study of chemotherapy, ICIs, and antiangiogenic agents

  • Open Access
  • NSCLC
  • Research

Approximately 40%–50% of patients with non-small cell lung cancer (NSCLC) develop brain metastases (BMs), a complication that significantly affects prognosis and quality of life [ 1 , 2 ]. Notably, around 25% of these patients exhibit BMs …

Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy

Immune checkpoint inhibitors (ICI) have become the new standard of treatment for advanced and recurrent non-small cell lung cancer (NSCLC). Inhibitors of programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) and cytotoxic T …

Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: clinical utility of subcategorizing interstitial lung abnormalities

Interstitial lung abnormalities (ILAs) are immune checkpoint inhibitor (ICI)-related pneumonitis (ICI-P) risk factors. However, the relationship between imaging patterns and immunotherapy outcomes, and treatment strategies remain unclear in …

Related topics

Tracheopericardial fistula masquerading as acute MI

Tracheopericardial fistula is often misdiagnosed due to its rarity and nonspecific presentation. In this patient with recurrent lung cancer, it was initially mistaken for an acute myocardial infarction.

Read more